Abstract: The present disclosure relates to a waveguide gasket arrangement arranged for electrically sealing a waveguide interface between a first waveguide end and a second waveguide end, where the waveguide gasket arrangement comprises a first plurality of electrically conducting members connected to a first common structure along a first circumference. The waveguide gasket arrangement further comprises a second plurality of electrically conducting members connected to a second common structure along a second circumference.

Abstract: A method and system for executing a security policy at a mobile terminal is provided. The mobile terminal may contact an authentication entity based on the security policy. The mobile terminal may receive a response from the authentication entity indicative of a security status of the mobile terminal. The mobile terminal may execute a security action based on the received response.

Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly, the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.

Abstract: The invention relates to a steering and propulsion arrangement for a ship. The inventive steering and propulsion arrangement comprises a screw propeller 3 and a rudder 6. A streamlined propulsion bulb 10 is made integral with or fixedly connected to the rudder. The invention also relates to a ship 2 provided with the inventive arrangement.

Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.

Abstract: The present invention relates to an arrangement, a network and methods for identifying the relevant SDP for a question from an SCP in a telecommunication network with a large amount of subscribers and handling and administration of a large amount of subscribers by introducing a function for intelligent routing. The intelligent routing between SCP and SDP can be handled by a node standing by itself in the network or as a part-function in an already existing node, for example an SCP. When a new subscriber shall be stored in an SDP subscriber data is transferred from the service administration to a master IRF (Intelligent Routing Function). The IRF comprises a function for determining which SDP that shall store the subscriber data and the IRF thereafter transfer the subscriber data to the SDP. The IRF also stores this information. The information is also transferred to the other IRFs. When an SCP gets a call from an SSP, the SCP contacts an IRF which contacts an SDP.

Abstract: The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. A method of screening compounds for their ability of inhibiting ligand-induced co-stimulatory receptor internalization pathways in immune competent human cells is described. Said immune competent human cells are incubated at conditions capable of inducing co-stimulatory receptor internalization in the presence of at least one test compound and the suppression of the ligand-induced co-stimulatory receptor internalization determined.